The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RICTOR amplification as a novel therapeutic target for lung cancer brain metastases.
 
Haiying Cheng
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - Roche/Genentech; Spectrum Pharmaceuticals; Vaccinex; Vaccinex
Patents, Royalties, Other Intellectual Property - Pat pending
 
Ni Fan
Employment - Eurofins
Patents, Royalties, Other Intellectual Property - Pat. Pending
 
Ethan Sokol
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Feng Wang
No Relationships to Disclose
 
Yiyu Zou
Patents, Royalties, Other Intellectual Property - Pat pending
 
Monica Feng
No Relationships to Disclose
 
Garrett M. Frampton
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Tushar Bhagat
No Relationships to Disclose
 
Amit Verma
Stock and Other Ownership Interests - Stelexis Therapeutics
Honoraria - Acceleron Pharma; Celgene; Stelexis Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Janssen Oncology (Inst)
 
Balazs Halmos
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Guardant Health; Lilly; Merck; Novartis; Pfizer; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Roman Perez-Soler
Stock and Other Ownership Interests - Stelexis Therapeutics
Consulting or Advisory Role - AZD; Boehringer Ingelheim; Clovis Oncology; Genentech/Roche; Merck Serono; Stelexis Therapeutics; Vertex